Proceedings of the Korean Society of Toxicology Conference (한국독성학회:학술대회논문집)

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지

Considerations in the Design of the Preclinical Safety Program for PegIntron

  • Davis, Thomas (Group Director, General Toxicology, Schering-Plough Research Institute, USA.)
  • Published : 2003.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

PegIntron is the pegylated form of human recombinant interferon alfa-2b (IFN${\alpha}$2b). IFN ${\alpha}$2b, known as Intron A, has been in approved clinical use since the 1980's for various cancer indications, and for the treatment of Hepatitis C. In the mid 1990's, several clinical investigators reported that combination therapy with ribavirin and Intron A dramatically increased the therapeutic efficacy for treatment of Hepatitis C.(omitted)

Keywords